Anteris Reports No Moderate or Severe Prosthesis-Patient Mismatch at 30 Days in Medium-Size DurAVR Study

• Anteris Technologies reported 30-day results for its medium-size DurAVR transcatheter heart valve in 22 severe aortic stenosis patients with medium-sized aortic annuli.
• Results were presented at the TCT 2026 conference in San Diego.
• The valve showed favorable blood-flow performance, with no valve-related deaths, moderate or severe leakage, or moderate or severe prosthesis-patient mismatch.
• The ongoing PARADIGM pivotal trial is enrolling patients to compare DurAVR with commercially available replacement valves; it will include the medium-size device.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anteris Technologies Global Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611011459PRIMZONEFULLFEED9867675) on November 01, 2026, and is solely responsible for the information contained therein.